MITOGEN ADVANCED DIAGNOSTICS

2018-19 Schedule of Autoantibody Tests & Turnaround Times

 

Name of Test/Assay Procedure/Technique Turn-around time (Days)*
Anti-Cellular Antibody IIF on HEp-2 substrate with pattern interpretation 5
Antiphospholipid syndrome:
·     anti-PS/PT: IgG, IgM (replaces lupus inhibitor
·     b2GP1 Domain 1
ELISA
CIA
5

5

Arthritis Profile: 
Anti-Citrullinated Peptide Profile: HCP1, HCP2, VCP1, VCP2; RF
ALBIA 5
ADAMTS-13 Activity & INH Profile:

·     ADAMTS-13 Activity

·     ADAMTA-13 Auto-antibodies/Inhibitors

 

ELISA

ELISA

 

1-2

1-2

Cancer Associated Autoantibody Panel:  p53, CENP-F ALBIA (LDT) 7
Cytoplasmic dot panel
(GW Bodies/GW182, Ago2, Ge-1; endosome/ EEA1)
ALBIA (LDT)  7
Dense Fine Speckles pattern: DFS70/LEDGF CIA  5-7
Dermatology: Bullous Autoimmune Dermatoses Profile CBA 5-7
DNA Antibodies
·       ssDNA
·       dsDNA (quanititative for SLE disease activity)
ELISA
CIA
5- 7
5
Drug-Induced Lupus: anti-histone ELISA 5-7
Gastrointestinal:
Inflammatory Bowel Disease ASCA (IgG, IgA)
ELISA 5
Liver:
Autoimmune Liver Disease panel (AIH/PBC): M2, M3/3E-BPO, gp210, SP100, SLA, PML, LC-1, Ro52
LIA 5-7
Lung: 
·       ILD Profile ( Antibodies to : Ro52, PDGFR, Ku, PM75, PM100, Th/To, NOR90, Fibr, RP155, RP11, CENPA, CENPB, Scl-70, OJ, EJ, PL-12, PL-7, SRP, Jo-1, SAE1, NXP2, MAD5, TIF1γ, Mi-2 β, Mi-2 α
·       Alveolar Proteinosis (GMCSF)
 

LIA

ALBIA (LDT)

 

5-7

5-7

Muscle: Inclusion Body Myositis: Anti-Mup44/NT5C1A ALBIA (LDT) 5-7
Muscle: Autoimmune Myositis Panel for Dermatomyositis, Polymyositis, Synthetase Syndrome: Jo‐1, Mi2, Mi2‐α, Mi2β, MDA5, NXP2, TIF1γ PL7, PL12, PM/Scl75, PM/Scl100, Ku, SRP, EJ, OJ, Ro52 LIA 5-7
Muscle:
Immune Mediated Necrotizing Myopathy
Statin Related Myopathy :
anti-HMGCR, anti-SRP
ELISA ,LIA 7
Nephritis:
· Idiopathic membranous nephropathy
Anti-PLA2R
· Primary Membranous Nephropathy
Anti-THSD7A
CBACBA 5-7

5-7

Neurological: Autoimmune
IgG and IgM Gangliosides: GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b
LIA 7
Neurological: 
Neuromyelitis Spectrum Profile: 
Anti-Aquaporin 4 (Anti-NMO)/Anti-Meylin Oligodendrocyte Glycoproteins ( Anti-MOG)
 

CBA

 

5-7

Neurological: Encephalitis

·            Anti- NMDA receptor: NR1

·            Anti-DPPX

·            VGKC

·            Anti-GABAB Receptor

·           Anti-AMPA Receptor

 

CBA
CBA
CBA
CBA
CBA

 

5
5
5
5
5

Neurological:
MAG (myelin associated glycoprotein)
LIA 7-10
Neurological:
Idiopathic Ataxia, MPP-1
ALBIA (LDT) 10
Neurological/Cancer:
Paraneoplastic  panel: Amphiphysin, Ri(NOVA‐1), Yo, Hu, PNMA2(Ma2/Ta), CV2/CRMP‐5, Recoverin, SOX1, Titin
LIA 5-7
Neurological: GAD65 CBA 5-7
Nuclear Envelope/Membrane  Profile(RUO): laminB, gp210, Tpr ALBIA(LDT) 7
Nucleolar Autoantibody Profile: PM/Scl, Th/To, fibrillarin, NOR-90, RNAP III IIF/ LIA 7
Scleroderma/Systemic Sclerosis Profile:
CENP A + B, Topo‐I/Scl‐70, RNA polymeraseIII, fibrillarin, Th/To, Ku, PDGFR, Ro52/TRIM21, PM/Scl‐75, PM/Scl‐100, NOR90/hUBF
LIA 5-7
Sjögren’s Syndrome Profile: 
SS-B/La, SS-A/Ro60, Ro52
LIA 5-7
Systemic Lupus Profile:
Sm, U1RNP, ribosomal P, dsDNA, SS-A/Ro60, SSB/La, Ro52, Ku, Chromatin, PCNA
LIA/ELISA 5
Vasculitis Panel:

·         ANCA( PR3,MPO)

·         Atypical ANCA (LAMP2, Elastase)

·         Anti-p140/p155/TRIM28

 

CIA
ABLIA
ABLIA

 

5-7
7
7

 Anti-IgLON5  CBA  7

 

Abbreviations:

AIH: autoimmune hepatitis; ALBIA: addressable laser bead immunoassay by Luminex; AMPAR: (a-amino-3-hydroxy-5-mehtyl-4-isoxasole proprionate receptor): limbic encephalitis ANA: antinuclear antibody; ASCA: anti-Saccharomyces cerevisiae antibody; CarP: carbamylated protein; CBA: cell based assay; CENP: centromere protein; CIA: chemiluminescence assay (BioFlash); DPPX: dipeptidyl peptidase like 6; EEA-1: early endosome antigen 1; ELISA: enzyme linked immunosorbent assay; GAD: glutamate decarboxylase; GM-CSF: granulocyte macrophage colony stimulating factor; IBD: inflammatory bowel disease; IIF: indirect immunofluorescence; LDT: Laboratory Develop Technology; LIA: line immunoassay; MAG: myelin associate glycoprotein; MecP2: methyl CpG binding protein 2; MPO: myeloperoxidase; MPP1: M-phase phosphoprotein 1; NMDA: N-methyl-D-aspartic acid; NMO: neuromyelitis optica spectrum (Devic’s Diseases); PBC: primary biliary cirrhosis; PR3: proteinase 3; PS/PT: phosphatidyl serine/prothrombin complex; SARD: systemic autoimmune rheumatic diseases (SLE, scleroderma, myositis, Sjögren’s syndrome); VGKC: voltage gated potassium channel,

 

Disease and Autoantibody Related Autoantibody Panels

  • Anti-phospholipid syndrome: anti-prothrombin/phosphatidyl serine complex (PS/PT): replaces lupus anti-coagulant/lupus inhibitor; b2GP1 Domain 1: more specific epitope for APS than intact b2GP1.
  • Arthritis Panel: Anti-Citrullinated peptide profile: 4 new citrullinated peptides including mutated vimentin/Sa,   Carbamylated protein (CarP), RF: rheumatoid factor.
  • Interstitial Lung Disease Profile: anti-MDA5, Jo1, PL-7, PL-12, Ro52/TRIM21, Th/To, Topo I.
  • Cell Cycle Profile: PCNA, CENP-F.
  • Nucleolar Antibody Panel: anti-PM/Scl75, Th/To, fibrillarin, RNA polymerase III
  • Nuclear envelope autoantibody Panel: anti-lamin B, gp210, Tpr
  • Scleroderma Profile: Th/To, topoisomerase I (Scl-70), PM/Scl, fibrillarin, PDGFR, PM/Scl 75, PM/Scl 100, RNA polymerase III, Ku.
  • Systemic Lupus Profile: anti-Sm, U1RNP, Ribosomal P, SSA/Ro60, anti-dsDNA, PCNA, anti-chromatin, Ku.
  • Systemic Lupus Erythematosus Disease Activity: dsDNA: for patients who were previously tested by Mitogen and clinician following anti-dsDNA titers as a parameter of disease activity.
  • Sjögren’s Syndrome Profile: anti-Ro52/TRIM21, SSB/La, SSA/Ro60.
Top